BioPharmSignal logoBioPharmSignal

Biotech News

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

Pliant Therapeutics (PLRX)Pliant TherapeuticsClinical readout

Selected for oral presentation at Clinical Trials Mini Symposium SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced

Related news

PLRXPliant Therapeutics2026-04-18 17:31 EST

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

PLRXPliant Therapeutics2026-04-30 12:30 EST

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

View all latest news

Pliant Therapeutics

Integrin-Targeted Drug Discovery Pliant Therapeutics is a clinical-stage biotechnology company developing therapies that modulate integrin-mediated biological pathways. Its current development focus centers on oncology and targeted drug delivery. PLN-101095 PLN-101095 is an oral small molecule that selectively inhibits the αvβ8 and αvβ1...

Recent company news

PLRXPliant Therapeutics2026-08-18 12:30 EST

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

PLRXPliant Therapeutics2026-08-11 20:05 EST

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PLRXPliant Therapeutics2026-07-13 12:30 EST

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

PLRXPliant Therapeutics2026-05-21 21:30 EST

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

PLRXPliant Therapeutics2026-05-11 20:05 EST

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Stock data

Close
1.10 USD
Market cap
71.83M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States